Neeraj Agarwal,
MD
Languages Spoken: English
Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI.
Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology and European Urology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.
Clinical Locations
Clinic 2B, GU
801-587-4644
Fax: (801) 585-0721
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.6/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
October 01, 2022
HUNTSMAN CANCER CENTER
Web froze shortly after the doctor joined the appointment.
UofU Patient
September 24, 2022
HUNTSMAN CANCER CENTER
Julia is the best
UofU Patient
September 12, 2022
HUNTSMAN CANCER CENTER
We have not gotten. To the stage of reatment
UofU Patient
August 27, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
August 24, 2022
HUNTSMAN CANCER CENTER
Dr. Agarwal is great!!!
UofU Patient
July 31, 2022
HUNTSMAN CANCER CENTER
Great visit. Dr took the time to explain the next phase of treatment He cares about you and your well-being.
UofU Patient
July 17, 2022
HUNTSMAN CANCER CENTER
All good. Though he is very busy, I was treated as though I was Dr. Agarwal's only patient. He always makes me feel as though he really cares.
UofU Patient
July 16, 2022
HUNTSMAN CANCER CENTER
We love Dr. Agerwal and his team.
UofU Patient
July 10, 2022
HUNTSMAN CANCER CENTER
Julia and Soffee were very helpful and friendly like always. Also saw Dr. Agarwal and he was friendly and positive.
UofU Patient
June 28, 2022
HUNTSMAN CANCER CENTER
The Best!
UofU Patient
May 27, 2022
HUNTSMAN CANCER CENTER
EXCELLENT consult. Very clear explanations and a sensible change in my previous treatment plan that I greatly appreciated.
UofU Patient
April 01, 2022
HUNTSMAN CANCER CENTER
Outstanding doctor and professional staff.
UofU Patient
April 01, 2022
HUNTSMAN CANCER CENTER
Dr Agarwal has always shown great concern and demonstrates a genuine interest in caring for me and my condition. He also offers support and encouragement.
UofU Patient
February 20, 2022
HUNTSMAN CANCER CENTER
I feel as though I have been left in limbo. I stopped taking my cancer meds in Dec. Nothing has been scheduled until 3/25. I was unable to participate in the clinical study because I was diagnosed with an infection. Since then, not much has happened.
UofU Patient
February 08, 2022
HUNTSMAN CANCER CENTER
All medical staff were kind caring and compassionate.
UofU Patient
January 28, 2022
HUNTSMAN CANCER CENTER
Dr Augarwal and his staff are the best, everyone knows me by name and make you feel well cared for.
UofU Patient
January 23, 2022
HUNTSMAN CANCER CENTER
Julia did a great job of explaining my new treatment.
UofU Patient
January 09, 2022
HUNTSMAN CANCER CENTER
The care and concern from Dr. Agerwal and his staff has / is amazing.
UofU Patient
December 30, 2021
HUNTSMAN CANCER CENTER
It all went very well
UofU Patient
November 17, 2021
HUNTSMAN CANCER CENTER
All good
UofU Patient
November 01, 2021
HUNTSMAN CANCER CENTER
Dr Agarwal has always been a tremendous help in answering all my questions. He has been the the best Doctor anyone could ask for this past seven years He definitely saved my life. I think the world of him. I think the world of this great man.
UofU Patient
October 08, 2021
HUNTSMAN CANCER CENTER
Dr Agarwal is always thinking and planning ahead in my treatment
UofU Patient
October 08, 2021
HUNTSMAN CANCER CENTER
I consider myself very fortunate to be under the care of Agarwal and his team
UofU Patient
October 07, 2021
HUNTSMAN CANCER CENTER
All good.
UofU Patient
October 04, 2021
HUNTSMAN CANCER CENTER
I have had the good fortune to have the care and expertise of Dr Agarwal and his team. Thanks to all.
UofU Patient
September 18, 2021
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
August 22, 2021
HUNTSMAN CANCER CENTER
Very thorough
UofU Patient
August 15, 2021
HUNTSMAN CANCER CENTER
Good informative visit
UofU Patient
August 13, 2021
HUNTSMAN CANCER CENTER
Very very good. Dr. Agarwal is awesome.
UofU Patient
August 11, 2021
HUNTSMAN CANCER CENTER
Both Julie (PAC) and Dr. Agarwall are exceptional.
UofU Patient
August 04, 2021
HUNTSMAN CANCER CENTER
I cannot say enough good about Dr Agarwal and the entire team in Clinic 2B
UofU Patient
July 23, 2021
HUNTSMAN CANCER CENTER
All good.
UofU Patient
July 22, 2021
HUNTSMAN CANCER CENTER
Julia is so good.
UofU Patient
July 11, 2021
HUNTSMAN CANCER CENTER
Julia Batten,RN,NP,is the very best.She has knowledge,patience,concern and a special manner giving us encouragement with our treatment and what we try to do on our part.Julia leads the staff with her concern & knowledge.Her special ways of executing care are followed by the staff.This makes Dr Agarwal's team the best !
UofU Patient
July 06, 2021
HUNTSMAN CANCER CENTER
I always have been made to feel supported and cared for
UofU Patient
June 19, 2021
HUNTSMAN CANCER CENTER
Dr Agarwal was encouraging and positive and reassuring. We had a very good visit
UofU Patient
June 11, 2021
HUNTSMAN CANCER CENTER
experience was good
UofU Patient
May 21, 2021
HUNTSMAN CANCER CENTER
good experience
UofU Patient
May 15, 2021
HUNTSMAN CANCER CENTER
Again, no one has explained the test results and their meaning. Also, I would like to know if Huntsman does "regional perfusion radiotherapy" done by other clinics in the U.S. I would also like to know what supplemental, alternative and/or natural treatments are worth trying.
UofU Patient
May 09, 2021
HUNTSMAN CANCER CENTER
dr agerwal was excellent and is getting me in a program
UofU Patient
May 07, 2021
HUNTSMAN CANCER CENTER
I love Dr. Agarwal he's the best
UofU Patient
April 25, 2021
HUNTSMAN CANCER CENTER
I am very pleased with the care received.
UofU Patient
April 23, 2021
HUNTSMAN CANCER CENTER
they really care about their patients
UofU Patient
April 20, 2021
HUNTSMAN CANCER CENTER
After almost a full day of tests, Dr. Agarwal spent less than 5 minutes with me. He told me that I didn't need to come back unless my PSA increased. He told me that if I had any questions I could call his nurse, Julia Batten, APRN, who did spend time reviewing one test that I had that day. I also find it interesting that no "Notes" or "Visit Summary" appear in My Chart as of today from either Dr. Agarwal nor Julia Batten. Dr. Agarwal does not appear on my lisrt of providers.
UofU Patient
April 17, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
April 11, 2021
HUNTSMAN CANCER CENTER
all good
UofU Patient
April 10, 2021
HUNTSMAN CANCER CENTER
Julia is always concerned,ready with patience and care.She has a listening ear and gives input explaining in a way that is undersstanble and how it is applicable to you in this particular stituation.We cannot say enough of how much Julia has given to improve our care in only her special way. This has been so important and means so much to our health and well-being. Thank you Julia !!!
UofU Patient
March 26, 2021
HUNTSMAN CANCER CENTER
good visit
UofU Patient
March 14, 2021
HUNTSMAN CANCER CENTER
Excellent care, couldn't ask for better
UofU Patient
March 11, 2021
HUNTSMAN CANCER CENTER
WONDERFUL AND CONCERNED STAFF
Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI.
Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology and European Urology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.
Academic Locations
Primary Children’s and Families’ Cancer Research Center
801-213-5658
(801) 585-0124
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
Research Interests
- Prostate Cancer
- Genitourinary Cancers
- Clinical Trials
- Bladder Cancer
- Kidney Cancer
Education History
| Fellowship | University of Utah School of Medicine Hematology/Oncology Fellow, 2007 |
| Fellowship | University of Iowa Hospitals and Clinics Geriatrics Fellow, 2004 |
| Residency | University of Iowa Hospitals and Clinics Internal Medicine Resident, 2003 |
| Internship | Advocate Illinois Masonic Medical Center Internal Medicine Intern, 2001 |
| Professional Medical | All India Institute of Medical Sciences Medicine M.D., 2000 |
Selected Publications - Journal Articles
Journal Article
- Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N (2022). SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res, 28(22), 4917-4925.
- Azad AA, Kostos L, Agarwal N (2022). KIT as a therapeutic target in neuroendocrine prostate cancer. Cancer Cell, 40(11), 1266-1268.
- Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, rn Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M (2022). Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA. Clin Cancer Res.
- Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK (2022). Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol.
- Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N (2022). External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. Mol Cancer Ther.
- Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 27(10), e815-e818.
- Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Seplveda Snchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B (2023). Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol, 8(10), 1411-1418.
- Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acua Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY (2022). ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene, 41(42), 4709-4723.
- Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N (2022). Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol, 12, 966534.
- Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583.
- Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA (2022). Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res, OF1-OF11.
- Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR (2022). Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer.
- Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw, 20(8), 866-878.
- Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol.
- Sahu KK, Tripathi N, Agarwal N, Swami U (2022). Relugolix in the management of prostate cancer. Expert Rev Anticancer Ther, 22(9), 1-12.
- Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U (2022). Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Eur Urol Focus.
- Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL (2022). The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discov, 12(7), 1620-1624.
- Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol, 23(7), 899-909.
- Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer.
- Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B (2022). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clin Genitourin Cancer, 20(3), e233-e243.
- Tjollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, Karsh L, Chi K, Chowdhury S, Ruixo JP, Agarwal N (2022). Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemother Pharmacol, 89(5), 629-641.
- Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI (2022). Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol, JCO2102517.
- Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR (2021). Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clin Genitourin Cancer, 20(2), 165-175.
- Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S (2022). A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol, 18(10), 1185-1198.
- Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N (2022). Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open, 5(3), e225394.
- Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K (2022). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol, 18(4), 425-436.
- George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandstrm P, Verholen F, Higano CS, Shore N (2022). Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis, 25(2), 306-313.
- Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A (2022). Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(1), 71-90.
Review
- Sayegh N, Tripathi N, Agarwal N, Swami U (2022). Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. [Review]. Onco Targets Ther, 15, 1047-1055.
- Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, Dorff TB, Gleave M, James ND, Poon DMC, Suzuki H, Sweeney CJ (2022). First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. [Review]. Eur Urol Oncol, 5(4), 377-387.
- Carril-Ajuria L, Martin-Sobern MC, de Velasco G, Agarwal N, Castellano D (2022). Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. [Review]. J Cancer Res Clin Oncol, 148(5), 1097-1105.
- Mathew Thomas V, Tripathi N, Agarwal N, Swami U (2022). Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. [Review]. Expert Rev Anticancer Ther, 22(4), 335-341.
Editorial
Other
Global Impact
Education History
| Professional Medical | All India Institute of Medical Sciences Medicine M.D. |